Why did it take 30 years to get the first drug for Alexander disease?

Zanvastro is the first approved treatment for Alexander disease. Its long path shows why rare-disease trials and delivering medicine to the brain are unusually difficult.

Zanvastro is the first FDA-approved treatment for Alexander disease, a rare neurological disorder. It is given once every three months by injection into the spinal canal and was studied in a 54-patient trial across 13 sites. Approval covers patients of all ages, a milestone built on decades of work to find enough participants and deliver a therapy past the brain’s defenses.

The same trial networks, genetic tools, and brain-delivery methods may help other rare-disease programs move faster.

Why rare-disease drugs take so long

Alexander disease affects very few people, so finding enough patients for a meaningful trial can take years. The treatment must also reach the brain, which is protected by strong natural defenses. Proving safety and benefit in such a small, scattered group is slow, careful work.

What to do, step by step

1. Learn the basics: this treatment is given by injection into the spinal canal, once every three months.
2. Ask the care team who the approval covers and whether it fits your situation.
3. Ask about monitoring, follow-up visits, and side effects to watch for at home.
4. Keep symptoms, questions, and appointment notes together for every specialist you see.
5. Contact a rare-disease support organisation for practical help and current guidance.